title: Erythropoietin for treating post-ivermectin Loa-related serious adverse events?
authors.forename: Michel
authors.initials: M
authors.lastname: Boussinesq
authors.forename: Joseph
authors.initials: J
authors.lastname: Kamgno
authors.forename: Sébastien D
authors.initials: SD
authors.lastname: Pion
authors.forename: Charles D
authors.initials: CD
authors.lastname: Mackenzie
mesh_terms: D000871:Anthelmintics / Q000009:adverse effects* / Q000627:therapeutic use; D004921:Erythropoietin / Q000494:pharmacology*; D006801:Humans; D007559:Ivermectin / Q000009:adverse effects* / Q000627:therapeutic use; D008118:Loiasis / Q000188:drug therapy*; D018696:Neuroprotective Agents / Q000627:therapeutic use*
chemical_list: D000871:Anthelmintics; D018696:Neuroprotective Agents; D004921:Erythropoietin; D007559:Ivermectin